Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer
Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships
Source Genomics expands sequencing portfolio with first UK commercial service on the Element Biosciences AVITI™ System
Cambridge, UK - Source Genomics, a part of the Source BioScience Group, announces their genomic laboratory expansion by adding an Element Biosciences AVITI™ System to its fleet of sequencers.
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market
Cambridge, UK, 30 January 2024: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), announces the appointment of Joseph Parisi as US Director of Sales.
SciTribe logo design
Angie Moyes writes...I worked with Dr Priya Kalia on her ‘SciTribe’ logo. Priya knew that she wanted a typewriter font and came to me to further develop the idea. Priya wanted her branding to feel more ‘together’ as her business, that offers strategic communications consulting focused on science & technology, was growing.
Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Round led by new investor Panakes, with participation from all existing investors Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in class ENaC blocker (ETD001) and pipeline expansionQueensgate awarded funding for fourth research project with NPL
Queensgate, a brand of Prior Scientific, has won funding from Innovate UK, the UK’s innovation agency, for a fourth nanopositioning research project as part of Analysis for Innovators (A4I) program (Round 11).
Asimov launches LV Edge Packaging System to optimize lentivirus production
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.
Don't miss your chance to enter the Cambridge Independent Science and Technology Awards 2024
The deadline is January 31.
EUROAPI enhances its CDMO capabilities through a pivotal collaboration with SpiroChem, a leading Contract Research Organization (CRO)
This collaboration will ensure the continuity of API development, from route scouting to process industrialization and GMP manufacturing EUROAPI and SpiroChem to provide clients with consolidated CRO-CDMO customized solutions to accelerate API chemical development and shorten timelines, especially for early-stage projects and the biotech segment. This agreement will strengthen EUROAPI’s Contract…
Transforming Healthcare Podcast: CES and the opportunities for the medical and health technology sector
In this episode, host, Jay Evans is joined by Dr Bipin Patel and a special guest for this podcast, Karla Pequenino, a journalist at Publico in Portugal.
Cellular Origins, a TTP Company, appoints Peter Crossley as Chief Operating Officer
Product and technology innovator will build team to further develop and deliver Cellular Origins’ products for cell and gene therapy manufacture at scaleCAMBRIDGE, UK - Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and e
Impact of the EU's general pharmaceutical legislation on Europe's innovation ecosystem and biotechnology companies
EuropaBio asked Charles River Associates to research the potential impact of the proposed changes included within the EU’s General Pharmaceutical Legislation (GPL) to Europe’s innovation ecosystem, with a particular focus on its impact on the growth of emerging and small biotechnology companies.
NIHR BioResource Scientific Conference to return in June 2024
NIHR BioResource are excited to announce the NIHR BioResource Scientific Conference will return later this year, hosted online on Wednesday 19 June 2024 from 9.30am to 12.30pm. Leading academics and industry researchers will present their recent work and the unique role of the NIHR BioResource in delivering translational research across a range of disease areas.
Elevating balance and vestibular care at angli-EAR Hearing with the arrival of James Saladine
angli-EAR Hearing proudly welcomes James Saladine, a highly experienced Balance and Vestibular Physiotherapist, to its expert team. With a background in Vestibular Rehabilitation Physiotherapy, James enhances the clinic's offerings, focusing on managing debilitating dizziness symptoms for clients and reducing the risk of falls through unsteadiness.
CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies
Cambridge, UK, and Durham, North Carolina, US - CN Bio and Altis Biosystems, Inc., leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, announces a strategic partnership.
PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood
Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial Assay will be available as a service in the BabrahamCalluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
· Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics · Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases
New NHS blood group genotyping test developed with BioResource launches today
From today, almost 18,000 people in England with sickle cell disorder and thalassaemia can have a world-first genetic test to better match future blood transfusions, reducing the risk of side effects.
Seeking managers for research interviews on workplace wellbeing decisions
The UEA workplace wellbeing team calls for UK managers of any level, any sector, to take part in new research about decision-making on workplace wellbeing activities.
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindnessDublin, Ireland, and Tampere, Finland - ERS Genomics Limited (‘ERS’), the CRISPR licensing Company,
The emerging business models for digital therapeutics
This article was originally published at Med Device Online.
Guardtech pledge to support NHS aseptic pharmacy units in 2024 after spike in enquiries
The Haverhill cleanroom construction experts have been inundated with enquiries from the nation’s healthcare heroes in recent months
Supporting a Phase III R&D strategy within the anti-infective space
Client Issue An emerging pharmaceutical company sought to evaluate Phase III development strategies for an anti-infective drug with potential to treat a range of patient populations.